[Asia Economy Reporter Lee Jung-yoon] Tium Bio announced on the 2nd that it has signed a joint clinical trial and drug support agreement with the U.S. MSD (Merck Sharp & Dohme Corp).
The joint clinical research involves conducting a Phase 1/2 clinical trial to evaluate the safety, tolerability, and pharmacokinetic characteristics of a combination therapy using Tium Bio's TGF-β and VEGFR2 inhibitor TU2218 and MSD's Anti PD-1 immuno-oncology drug Keytruda in patients with advanced cancer.
The company stated, "The probability of a clinical trial drug ultimately receiving drug approval is statistically known to be about 10%," and added, "There is a possibility that the clinical trial and approval process may yield results that do not meet expectations, and accordingly, the company may change or abandon its commercialization plans."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
